PET—CT在淋巴瘤中应用的最新进展：第54届美国血液学会年会深度报道

Report on recent use of PET-CT in lymphoma in the 54th ASH annual meeting

由于PET—CT兼具解剖和组织功能学表现，其在淋巴瘤中的应用日益广泛。PET—CT主要被用于弥漫大B细胞淋巴瘤（DLBCL）和霍奇金淋巴瘤（HL）的分期和预后评估。目前有多项正在进行中的临床试验研究了PET—CT的应用。此外，PET—CT的评价标准如视觉评估（Deauville5分制）、最大标准摄取值（SUV）差值（ASUV_PET0-i）和基线肿瘤代谢活性体积（MTVO）对疾病预后评价的能力不同。但目前的研究仍限于临床试验，如何提高PET．CT的阳性和阴性预测能力及判断预后优劣还有待进一步探究，以期指导临床治疗方案的选择。

Positron emission tomography-computed tomography （PET-CT） with both anatomic and functional information is now widely utilized for most lymphoma subtypes, among which, the pretreatment staging and response assessment of PET-CT in Hodgkin lymphoma （HL） and diffuse large B-cell lymphoma （DLBCL）have been well documented. Multiple clinical trials are ongoing using PET-CT for therapy monitoring. Additionally, factors interpreting interim PET （PET-i） like visual analysis using Deauville 5-PS, metabolic tumor volume at baseline （MTV0）, and △ SUVmaxPET0-i show different prognostic values. However, the management of PET-CT in lymphoma is still elusive, further trials remain to be done to get evidences for the use of PET-CT in guiding therapeutic decisions.